Table 2 Efficacy results from single arm phase II studies of sotorasib (CodeBreaK100 [94]) and adagrasib (KRYSTAL-1 [100]) in NSCLC
From: Drugging KRAS: current perspectives and state-of-art review
| Â | Evaluable KRAS G12C NSCLC | Response rate 9) (%) | Median time to response (months) | Median duration of response (months) | Median PFS (months) | Median survival (months) |
|---|---|---|---|---|---|---|
Sotorasib 920Â mg daily | 124 | 37.1 | 1.4 | 11.1 | 6.8 | 12.5 |
Adagrasib 600Â mg bid | 112 | 42.9 | 1.4 | 8.5 | 6.5 | 12.6 |